Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03016819 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

325

Enrollment

INDUSTRY

Sponsor class

Conditions

Alveolar Soft Part Sarcoma
Leiomyosarcoma
Synovial Sarcoma
Soft-Tissue Sarcoma

Interventions

DRUG: AL3818
DRUG: Dacarbazine
DRUG: AL3818 or placebo
DRUG: Midazolam 2 mg for CYP3A4 phenotyping
DRUG: Digoxin (0.25mg)
DRUG: Rosuvastatin 10 mg tablet.

Sponsor

Advenchen Laboratories, LLC